Roche has established a strategic alliance with med fusion LLC in Lewisville, Tex, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

As a nationally recognized Roche MCOE, med fusion’s molecular diagnostics laboratory will offer physicians and patients some of the latest and most advanced molecular technologies, such as Roche’s cobas 4800 BRAF V600 Mutation Test, a companion diagnostic approved by the FDA in 2011 to identify patients who are eligible for treatment with the drug ZELBORAF (vemurafenib) for inoperable or metastatic melanoma, a deadly form of skin cancer.

Established in 2002, Roche’s MCOE program is designed to create an alliance network that enables non-competing regional laboratories across the U.S. to collaborate and capitalize on scientific knowledge in molecular testing and, in turn, help accelerate the advancement of new test methods and technology.

Source: Roche